Vyome Holdings, Inc HIND
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-50.57
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $319,714 | -$10.3M | $218,771 | — | $3.8M |
| 2024 | $256,944 | -$1.4M | $194,970 | — | -$4.4M |
| 2023 | $8.7M | -$11.4M | $5.5M | — | -$6.2M |
| 2022 | $11.2M | -$46.2M | $6.8M | — | $3.7M |
| 2021 | $13.6M | -$63.1M | $8.3M | — | $44.3M |
| 2020 | $11.3M | -$21.6M | $6.3M | -$8.7M | $14.5M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -50.57 (distress)
- Working capital / assets 0.416
- Retained earnings / assets -13.477
- EBIT / assets -1.609
- Equity / liabilities 1.375
Source: SEC EDGAR filings · CIK 0001427570 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.